

Dasatinib

Dasatinib (Sprycel, BMS-354825) is an oral BCR-ABL, c-KIT, SRC inhibitor (IC₅₀=<1, 79, and 0.8, respectively) and cancer drug developed by Bristol-Myers Squibb. FDA approved for treatment of chronic myelogenous leukemia (CML) and philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Materials Provided

Catalog Number:	92-1183
Quantity Supplied:	1 vial(s), 10 mg (re-packaged) per vial

Description

DiscoverX control ligands have been functionally tested and validated for optimal use with all cell line targets and Assay Ready kits.

Product Information

Molecular Weight:	488.01 g/mol
Source:	Synthetic
Purity:	≥ 99%
Endotoxin Level:	N/A
Formulation:	N/A
Storage:	≤ -20°C Please avoid multiple freeze/thaw cycles.

Reagent Preparation

To avoid condensation, equilibrate the vial to ambient temperature before opening.

Stock Concentration:	10 mM
Reconstitution Volume:	2.05 mL for 10 mg
Reconstitution Solvent:	DMSO

For Research Use Only

Ordering: +1.510.979.1415 option 4 or e-mail CustomerServiceDRX@eurofins.com
Technical support: +1.510.979.1415 option 5 or e-mail DRX_SupportUS@eurofinsUS.com
General product information: www.discoverx.com